Helex raises $3.5M to advance its genetic kidney disease treatments

Helex, a biotech startup, raised $3.5M seed funding led by pi Ventures to advance genetic kidney disease treatments. Funds support its ADPKD drug, kidney-tropic LNP delivery, and Epic-Cure 3D genome drug design. Founded by Chaudhuri, Nishtala, and Kalvakuntla, Helex expands into other kidney indications as India’s therapeutics market nears $52.4B by 2035.